## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tb-500-glp1-gut`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tb-500-glp1-gut/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-glp1-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-glp1-gut/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tb-500-glp1-gut/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-glp1-gut/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tb-500-glp1-gut/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tb-500-glp1-gut` v2 · content_hash `12ecb91316b7b131…` · thread_head genesis · 25 DIVs
- **thesis (c1):** Thymosin beta-4 / TB-500 evidence is largely preclinical with human data limited to wound/skin and ocular contexts.
  - c2 [human/active] GLP-1 agonists reproducibly delay gastric emptying in humans as a class effect.
  - c3 [human/active] No human trials exist for TB-500 or thymosin beta-4 in gastroparesis or GLP-1 gut damage.
  - c4 [anecdotal/active] Reddit users discuss TB-500 mainly in general recovery stacks rather than specific GLP-1 gastroparesis reversal.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tb-500-glp1-gut/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tb-500-glp1-gut/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tb-500-glp1-gut`
- **title:** TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows
- **url:** https://miscsubjects.com/a/tb-500-glp1-gut
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:14.998Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have GLP-1 gut damage / gastroparesis

GLP-1 receptor agonists slow gastric emptying as part of their intended action on gut motility. In some people this effect becomes pronounced and persistent, producing symptoms that overlap with gastroparesis. The core issue is delayed stomach emptying that can lead to nausea, bloating, early satiety, and in rarer cases more serious motility problems.

Repair-versus-degeneration framing applies here. The drug suppresses a motility signal to achieve metabolic benefits. When that suppression outruns the gut's ability to maintain normal function or recover normal motility, the problem persists. No direct tissue destruction occurs in most cases, but prolonged slowed transit can stress the enteric nervous system and smooth muscle layers that coordinate emptying.

## Why TB-500 might help you

1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.
2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

If GLP-1 agonist use has left gut motility slowed and local repair processes lagging, the logic chain points to whether actin-based cell movement can be supported. TB-500 fragments of thymosin beta-4 bind actin and are studied in preclinical models for promoting cell migration to sites of tissue stress. That migration step is one of the early requirements for clearing stalled inflammatory signals and allowing structural reorganization of smooth muscle or mucosal layers.

The if-then is narrow: only if actin disorganization or failed cell recruitment is contributing to your specific motility lag would this pathway be relevant. It does not reverse the GLP-1 receptor signal itself.

## Why GLP-1 agonists (class) matters for you

GLP-1 agonists (class) support metabolism by enhancing insulin response, slowing gastric emptying, and reducing appetite. The same motility slowing that aids glycemic control and weight loss can trade off against normal gut transit in susceptible individuals. This is suppression of a signal rather than reduction of mechanical load. The metabolic support is the primary benefit; any gut slowing is a known mechanism-based effect that usually attenuates but can persist or intensify in some users. For someone already experiencing gastroparesis-like symptoms, the tradeoff is direct: continued use maintains the metabolic benefit while the motility signal remains suppressed.

## How these fit together

Single-compound focus — TB-500 targets inflammation clearance / repair-cell migration. GLP-1 agonists provide metabolic support at the cost of motility suppression. The two do not directly interact in studied pathways; one addresses downstream repair questions while the other maintains the upstream metabolic change. Any combined discussion stays at the level of separate layers rather than claimed synergy.

## What the evidence actually shows

Human data on TB-500 or thymosin beta-4 for gut motility or gastroparesis is absent. Scoping reviews of thymosin beta-4 and TB-500 map evidence primarily to wound healing, ocular repair, and vascular contexts, with human trials concentrated in skin/soft tissue and cornea settings (source s10). No included human studies address intestinal smooth muscle or enteric repair.

Preclinical (mostly rodent and cell) work shows thymosin beta-4 promotes cell migration via actin sequestration and supports angiogenesis and reduced fibrosis in various tissues. These findings remain animal or in-vitro and do not establish translation to human GLP-1-related gastroparesis.

GLP-1 agonist effects on gastric emptying are documented in multiple human mechanistic and clinical studies; delayed emptying is a reproducible class effect that can meet diagnostic thresholds for gastroparesis in a subset of users (sources s0, s1, s3).

## What scientists say

Researchers note that thymosin beta-4 is an endogenous actin-sequestering protein with roles in embryonic development and adult tissue repair, yet large-scale randomized human trials for gastrointestinal applications are lacking. Reviews emphasize that while preclinical signals exist for cell migration and inflammation modulation, direct musculoskeletal or gut human evidence is sparse and largely preclinical (source s10). For GLP-1 agonists, clinicians document the motility effect as expected pharmacology rather than an off-target toxicity in most cases, with individual variability in persistence of symptoms.

## What people say on Reddit

Anecdotal reports mention peptides including TB-500 in stacks with BPC-157 for general recovery or gut comfort, but specific accounts tying TB-500 to reversal of GLP-1-induced gastroparesis are rare and unverified. Users sometimes discuss BPC-157 more frequently for GI symptoms, with TB-500 described in broader soft-tissue contexts. Posts note that any perceived gut benefits remain self-reported and coincide with other lifestyle changes (sources s29–s38).

## What people say on X

Public posts on X echo similar themes: occasional mentions of thymosin beta-4 or TB-500 for tissue repair in general, with very limited discussion of gut-specific outcomes in the context of GLP-1 agonists. No high-visibility threads with documented before-and-after motility testing appear in standard searches.

## What we do not know

Whether TB-500 alters GLP-1 receptor signaling, restores gastric pacemaker activity, or accelerates recovery of enteric neurons after prolonged agonist exposure is unknown. No pharmacokinetic studies examine TB-500 in the setting of concurrent GLP-1 agonist use. Long-term human safety data for TB-500 remain limited outside approved indications for related thymosin compounds.

## Safety and limits

TB-500 is not FDA-approved for any indication. Human clinical trial data are confined to small pilot studies in cardiac or wound settings. Any discussion of its use occurs outside approved medical practice. GLP-1 agonists carry labeled warnings for gastrointestinal effects including delayed emptying; persistent symptoms warrant medical evaluation rather than self-experimentation with research compounds. All claims above are graded by evidence tier and separated by study type; none constitute medical advice.

## Claims (4)

- **c2** [human w=0.8] GLP-1 agonists reproducibly delay gastric emptying in humans as a class effect.
  - who_claims: grok/grok-4.3
  - sources: s0, s1, s3
- **c3** [human w=0.8] No human trials exist for TB-500 or thymosin beta-4 in gastroparesis or GLP-1 gut damage.
  - who_claims: grok/grok-4.3
  - sources: s10
- **c1** [preclinical w=0.5] Thymosin beta-4 / TB-500 evidence is largely preclinical with human data limited to wound/skin and ocular contexts.
  - who_claims: grok/grok-4.3
  - sources: s10
- **c4** [anecdotal w=0.3] Reddit users discuss TB-500 mainly in general recovery stacks rather than specific GLP-1 gastroparesis reversal.
  - who_claims: grok/grok-4.3
  - sources: s29

## Voxel graph (4 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/tb-500-glp1-gut/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `ff15e639b1dd791c`

### s0 · pubmed · ok
- title: GLP-1 receptor agonists and delayed gastric emptying
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11620716/
- summary: Review of mechanisms linking GLP-1 agonism to gastroparesis symptoms in humans.
- quote: This paper explores the intricate connection between GLP-1 and delayed gastric emptying, specifically gastroparesis.
- claim_ids: c2
- hash: `833b961891176fbc`

### s1 · review · http_403
- title: Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
- url: https://academic.oup.com/jcem/article/110/1/1/7824836
- summary: Documents human clinical consequences of motility slowing.
- quote: While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through...
- claim_ids: c2
- hash: `96ef0beb455afdef`

### s3 · other · ok
- title: Incidence of Gastroparesis with GLP-1 Medications
- url: https://www.fellahealth.com/guide/incidence-of-gastroparesis-with-glp-1
- summary: Summarizes mechanistic and incidence data in humans.
- quote: GLP-1 receptor agonists intentionally slow gastric emptying as part of their therapeutic mechanism...
- claim_ids: c2
- hash: `d2ccf63098a3aff5`

### s10 · review · http_403
- title: Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
- url: https://www.mdpi.com/2076-3417/16/12/6202
- summary: 2026 scoping review mapping 80 studies; confirms limited human data outside skin/eye and absence of gut-specific trials.
- quote: The evidence base was weighted toward mixed and in vitro designs... Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study.
- claim_ids: c1, c3
- hash: `d4ae7fb9414932a0`

### s29 · reddit · ok
- title: How many of you have experienced permanent intestinal...
- url: https://www.reddit.com/r/Peptides/comments/1b7mwv8/how_many_of_you_have_experienced_permanent/
- summary: Example of GLP-1 gut discussion on Reddit with limited peptide specificity.
- quote: There is a glp-1 protein drink by Biocare that contains enzymes. Perhaps my story is not unique then?
- claim_ids: c4
- hash: `ff15e639b1dd791c`

## Provenance (2 model passes)
- chain valid: yes · head: `1892f9fd7861c5fb`

- write · grok/grok-4.3 · 2026-06-29T23:38 · hash `091708dfeee7`
- voxel_divide · owner · 2026-07-17T02:42 · hash `1892f9fd7861`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tb-500-glp1-gut/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tb-500-glp1-gut/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tb-500-glp1-gut","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tb-500-glp1-gut|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tb-500-glp1-gut|tier|assertion`
- **iMessage ask:** `tb-500-glp1-gut|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tb-500-glp1-gut`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-glp1-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-glp1-gut/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*